Eli Lilly chairman, president and CEO John Lechleiter has claimed that biopharmaceuticals should be included in transatlantic trade and economic discussions in order to promote innovation.
Speaking at the Transatlantic Partnership in the 21st Century conference held in Germany, Lechleiter said that biopharmaceutical innovation can pose substantial benefits to the global economy.
“New medicines are one of the most cost-effective investments we can make to improve health care and enable more efficient use of health care budgets,” said Lechleiter.
“We must ensure that health care reform in our countries will help promote biopharmaceutical innovation and not undermine it.”
Lechleiter continued to claim that short-term cost pressures enforced by governments are triggering responses that are hampering the sector, and called for consistent regulatory policies and intellectual property proportion to maintain medical innovation.